Cargando…

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

BACKGROUND: Acute myeloid leukemia (AML) remains a difficult disease to treat and requires new therapies to improve treatment outcome. Wee1 inhibitors have been used to prevent activation of the G2 cell cycle checkpoint, thus enhancing the antitumor activity of DNA damaging agents. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Wenxiu, Xie, Chengzhi, Li, Chunhuai, Caldwell, J Timothy, Edwards, Holly, Taub, Jeffrey W, Wang, Yue, Lin, Hai, Ge, Yubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237862/ https://www.ncbi.nlm.nih.gov/pubmed/25084614 http://dx.doi.org/10.1186/s13045-014-0053-9

Ejemplares similares

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775
por: Hauge, Sissel, et al.
Publicado: (2019)

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016)

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
por: Kreahling, Jenny M., et al.
Publicado: (2013)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2018)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2017)

Acute Myeloid Leukemia Cells Harboring MLL Fusion Genes or with the Acute Promyelocytic Leukemia Phenotype Are Sensitive to the Bcl-2-selective Inhibitor ABT-199
por: Niu, Xiaojia, et al.
Publicado: (2014)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2019)

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016)

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
por: Serpico, Angela Flavia, et al.
Publicado: (2019)

Wee1 and Chk1 – crosstalk between key players in replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
por: Zhou, Liang, et al.
Publicado: (2014)

WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment
por: Okabe, Seiichi, et al.
Publicado: (2023)

Chk1 and Wee1 kinases coordinate DNA replication, chromosome condensation, and anaphase entry
por: Fasulo, Barbara, et al.
Publicado: (2012)

Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells
por: Mak, Joyce P.Y., et al.
Publicado: (2015)

Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
por: Bi, Shuning, et al.
Publicado: (2019)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer
por: Wang, Qiming, et al.
Publicado: (2023)

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
por: Guertin, Amy D, et al.
Publicado: (2012)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation
por: Zhao, Xiaoliang, et al.
Publicado: (2021)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis
por: Chen, Dongshao, et al.
Publicado: (2018)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
por: Xu, Xuelian, et al.
Publicado: (2011)

Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP–E2F1–DNA damage response pathway axis
por: Oku, Yusuke, et al.
Publicado: (2018)

Curcumin Down-Regulates DNA Methyltransferase 1 and Plays an Anti-Leukemic Role in Acute Myeloid Leukemia
por: Yu, Jianhua, et al.
Publicado: (2013)

Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
por: Cui, Qingbin, et al.
Publicado: (2019)

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
por: Sørensen, Claus Storgaard, et al.
Publicado: (2012)

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
por: Magnussen, Gry Irene, et al.
Publicado: (2015)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy
por: Zhou, Zhi-rui, et al.
Publicado: (2017)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
por: Knight, Tristan E., et al.
Publicado: (2022)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
por: Bauer, Todd M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5u45hcf68g212pjl9vhi0vio37